Recent 8-K filings for OABI

• August 6, 2026, 4:11 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  OmniAb Q2 revenue surges to $13.4M; raises full-year 2026 revenue and cash outlook

  Q2 2026 revenue $13.4M vs $3.9M YoY, driven by milestone revenue and new ion channel programs.

• July 13, 2026, 8:06 AM ET leadership materiality 0.60 neutral item 5.02

  OmniAb appoints Amechi Nwachuku as COO effective July 13, 2026

  Amechi Nwachuku appointed COO, effective July 13, 2026; most recently VP at Thermo Fisher Scientific.

• June 18, 2026, 4:29 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  OmniAb shareholders elect directors Cochran and Foehr, ratify EY as auditor

  Jennifer Cochran, Ph.D. elected with 57,948,696 votes for, 25,997,984 withheld, 18,464,904 broker non-votes.

• May 7, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  OmniAb Q1 revenue $14.4M vs $4.2M YoY; raises 2026 guidance

  Revenue Q1 2026 $14.4M (up 243% YoY) driven by milestone revenue.

• March 4, 2026, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases ×3

  OmniAb Q4 net loss $14.2M; FY 2025 revenue down 29% YoY; guides 2026 rev $25-30M

  Q4 2025 revenue $8.4M (down 22% YoY from $10.8M); net loss $14.2M ($0.11/share).

• January 30, 2026, 6:59 PM ET other materiality 0.30 neutral item 5.03item 9.01 ◈ Governance Changes

  OmniAb amends bylaws to adopt universal proxy rules and enhance stockholder proposal disclosures

  Board approved amended bylaws effective January 30, 2026, adding universal proxy rule compliance language.

• November 4, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  OmniAb Q3 revenue falls 48% to $2.2M; net loss $0.14; raises FY revenue guidance to $18-22M

  Revenue $2.2M vs $4.2M in Q3 2024, driven by lower milestones and service revenue from discontinued ion channel programs.

• August 25, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 7.01item 9.01

  OmniAb raises $30M via private placement of 21.3M shares at $1.40/$1.85 per share

  Private placement of 21,254,106 common shares at $1.40 (or $1.85 for insiders) for gross proceeds of ~$30M.

• August 6, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  OmniAb reports Q2 2025 revenue $3.9M, net loss $15.9M; affirms $20-25M FY revenue guidance

  Q2 revenue $3.9M (down 49% YoY) on lower milestone and service revenue; net loss $15.9M ($0.15/sh) vs $13.6M ($0.13) in Q2 2024.

• June 18, 2025, 7:59 PM ET other material materiality 0.05 neutral item 5.07

  OmniAb shareholders elect two Class III directors and ratify EY auditor at 2025 annual meeting

  Carolyn R. Bertozzi, Ph.D. elected with 36,153,128 votes for, 31,275,065 withheld, 16,933,628 broker non-votes.

• May 8, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  OmniAb Q1 2025 revenue $4.2M (+10% YoY), net loss $18.2M; lowers opex guidance

  Q1 revenue $4.2M (vs $3.8M in Q1 2024); net loss $18.2M ($0.17/share) vs $19.0M ($0.19/share) prior year.

• April 21, 2025, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 ◈ executive_change ×2

  OmniAb appoints two new independent directors; Sarah Boyce resigns

  Sarah Boyce resigned from Board and all committees effective April 18; no disagreement with company.

• March 18, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  OmniAb Q4 rev $10.8M, net loss $13.1M; guides FY25 rev $20-25M, opex $90-95M

  Q4 revenue $10.8M (up from $4.8M YoY); net loss $13.1M ($0.12/shr) vs $14.1M loss prior year.

• November 12, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  OmniAb Q3 2024 revenue $4.2M (down 24% YoY), net loss $16.4M; partner pipeline grows

  Q3 2024 revenue $4.2M (down 24% YoY); net loss $16.4M ($0.16/sh) vs $15.7M ($0.16/sh) in Q3 2023.

• August 8, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  OmniAb Q2 revenue $7.6M, net loss $0.13/sh; guides 2024 opex slightly below 2023

  Q2 2024 revenue $7.6M (+10% YoY), net loss $13.6M ($0.13/sh) vs $14.7M loss in Q2 2023.

• July 1, 2024, 7:59 PM ET leadership materiality 0.25 neutral item 5.02 ◈ executive_change

  Director Joshua Tamaroff resigns from OmniAb Board; Audit Committee vacancy filled

  Joshua Tamaroff resigned from Board and Audit Committee effective June 28, 2024, due to pending departure from Avista Capital Partners.

• June 21, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

  OmniAb shareholders elect Boyce and Love as Class II directors; ratify EY as auditor

  Shareholders elected Sarah Boyce and Steve Love as Class II directors for three-year terms expiring 2027.

• May 9, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  OmniAb Q1 2024 revenue drops to $3.8M; net loss widens to $19.0M

  Revenue $3.8M vs $16.9M YoY; net loss $19.0M ($0.19/share) vs $6.1M ($0.06/share) loss.

• March 20, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  OmniAb Q4 revenue $4.8M, net loss $14.1M; 77 partners, 32 programs in clinic; guides 2024 op ex flat

  Q4 2023 revenue $4.8M vs $35.3M in Q4 2022, primarily due to $25M milestone in prior year.

• November 9, 2023, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases

  OmniAb Q3 revenue falls 20% to $5.5M; net loss widens to $15.7M

  Q3 2023 revenue $5.5M (down 20% YoY); net loss $15.7M ($0.16/share) vs $12.6M loss in Q3 2022.

• November 1, 2023, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change

  OmniAb appoints Steven Love to Board of Directors, effective Nov 1, 2023

  Steven Love appointed to Board; will serve as Chair of Audit Committee and member of Compensation Committee.

• August 10, 2023, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01 ◈ Earnings Releases

  OmniAb Q2 2023 revenue $6.9M, net loss $14.7M; adds four partners including Merck

  Q2 revenue $6.9M (vs $7.2M YoY); net loss $14.7M ($0.15/share) vs $10.3M loss YoY.

• June 26, 2023, 7:59 PM ET other materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×2

  OmniAb stockholders elect two Class I directors and ratify auditor at 2023 annual meeting

  Matthew W. Foehr and Jennifer Cochran, Ph.D. elected as Class I directors for three-year terms expiring 2026.

• May 11, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  OmniAb Q1 2023 revenue $16.9M, net loss $6.1M; 301 active partner programs

  Revenue $16.9M, up from $9.6M YoY, driven by $10.0M milestone from TECVAYLI EU commercial sale.

• March 31, 2023, 7:59 PM ET other materiality 0.00 neutral item 8.01item 9.01

  OmniAb amends auditor consent to fix typographical error in report date

  Corrected date of Ernst & Young auditor's report in Exhibit 23.2 to 10-K for year ended Dec 31, 2022.

• March 30, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  OmniAb Q4 revenue $35.3M, net income $6.8M; record 13 new partnerships in 2022

  Q4 revenue $35.3M (up from $15.3M YoY) driven by $25M TECVAYLI milestone; net income $6.8M vs loss of $3.1M.

• January 9, 2023, 6:59 PM ET other material materiality 0.50 neutral item 2.02item 7.01item 9.01

  OmniAb reports preliminary year-end cash of ~$88M; attending J.P. Morgan conference

  Preliminary unaudited cash, cash equivalents and marketable securities as of Dec 31, 2022: approximately $88M.

• November 18, 2022, 6:59 PM ET other material materiality 0.60 positive item 8.01

  OmniAb expects $25M milestone payment from Janssen after first US commercial sale of TECVAYLI

  Janssen notified OmniAb that first US commercial sale of TECVAYLI (teclistamab) occurred, triggering $25M milestone.

• November 15, 2022, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  OmniAb Q3 2022 revenue $6.9M, net loss $12.6M; completed spin-off from Ligand

  Revenue $6.9M in Q3 2022 vs $6.3M in Q3 2021; net loss $12.6M vs $7.9M.

• November 14, 2022, 6:59 PM ET other material materiality 0.65 neutral item 2.01item 9.01

  OmniAb reports $23.7M revenue, $29.2M net loss for nine months ended Sep 30, 2022

  Revenue for nine months ended Sep 30, 2022 was $23.7M, up 22% from $19.5M in 2021.

• November 7, 2022, 6:59 PM ET other material materiality 0.60 neutral item 4.01item 5.03item 5.05item 8.01item 9.01 ◈ Governance Changes ×3◈ Auditor Changes ×2

  OmniAb files 8-K/A: Auditor changed to EY, pro forma shows $390.6M assets, 114.8M shares outstanding after SPAC close

  Dismissed Marcum as auditor, engaged EY as new independent registered public accounting firm effective Nov 1, 2022.

• November 7, 2022, 6:59 PM ET M&A materiality 0.85 neutral item 1.01item 2.01item 5.06item 3.02item 3.03item 5.03item 5.01item 5.02item 9.01 ◈ M&A Transactions ×2◈ Governance Changes◈ Material Agreements

  OmniAb completes business combination with Avista Public Acquisition Corp. II, begins trading on Nasdaq

  Business combination closed on Nov 1, 2022; APAC domesticated as OmniAb, Inc. (DE) and merged with Legacy OmniAb.

• October 24, 2022, 7:59 PM ET M&A materiality 0.75 neutral item 5.02item 5.07item 8.01item 9.01

  Avista Public Acquisition Corp. II shareholders approve OmniAb business combination; ~97% of public shares redeemed

  All proposals approved at Oct 24 meeting including business combination, domestication, governance, director elections.

• August 25, 2022, 7:59 PM ET regulatory materiality 0.30 neutral item 3.01item 5.02 ◈ executive_change

  Avista Public Acquisition Corp. II appoints Charles Harwood to board and audit committee to regain Nasdaq compliance

  On Aug 22, 2022, company discussed Nasdaq Listing Rule 5605(c)(2) compliance after phase-in period.

• June 21, 2022, 7:59 PM ET other material materiality 0.25 neutral item 7.01item 9.01

  APAC files OmniAb teach-in presentation with no new material facts beyond prior deal terms

  Presentation attached as Exhibit 99.1 consists only of legal disclaimers and forward-looking statements.

• March 24, 2022, 7:59 PM ET M&A materiality 0.90 neutral item 1.01item 3.02item 9.01

  Avista SPAC to combine with OmniAb (Ligand antibody business) at $850M pre-money value

  OmniAb valued at $850M pre-money; earnout of up to 15M shares with $12.50/$15.00 VWAP targets.

• March 23, 2022, 7:59 PM ET M&A materiality 0.85 neutral item 8.01item 9.01

  APAC to merge with Ligand's OmniAb antibody discovery business at $850M valuation

  Pre-money equity valuation of $850M; minimum $130M gross cash to combined company, up to $266M.

• March 14, 2022, 7:59 PM ET debt materiality 0.30 neutral item 2.03item 9.01

  Avista Public Acquisition Corp. II issues up to $750K promissory note to sponsor for working capital

  Unsecured note of up to $750,000 issued on March 14, 2022 to sponsor Avista Acquisition LP II.

• January 28, 2022, 6:59 PM ET other material materiality 0.50 negative item 8.01item 9.01

  Avista Public Acquisition restates Aug 2021 balance sheet; reclassifies 23M shares to temporary equity

  Restatement reclassifies all 23M Class A ordinary shares from permanent to temporary equity; no cash impact.

• December 1, 2021, 6:59 PM ET other material materiality 0.70 negative item 4.02

  Avista Public Acquisition Corp. II restates prior financials over share classification error

  Restating audited balance sheet as of Aug 12, 2021 and Q3 2021 financials due to classification error on redeemable Class A ordinary shares.

• September 27, 2021, 7:59 PM ET other material materiality 0.20 neutral item 8.01item 9.01

  Avista Public Acquisition Corp. II units separate into AHPA and AHPAW on Sept 30

  Holders of 23,000,000 units can elect to separately trade Class A ordinary shares (AHPA) and warrants (AHPAW) starting Sept 30, 2021.

• August 18, 2021, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Avista Public Acquisition Corp. II closes $230M IPO plus $12.35M private placement; trust $235.75M

  Sold 23M units at $10 each, including full over-allotment; gross proceeds $230M.

• August 12, 2021, 7:59 PM ET other material materiality 0.70 neutral item 8.01item 9.01

  Avista Public Acquisition Corp. II closes $230M IPO, $235.75M in trust

  IPO of 23M units at $10/unit, including full over-allotment of 3M units.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

4 positive 6 negative 33 neutral

source · OABI on sec.gov